Back to top
more

OncoCyte (OCX)

(Real Time Quote from BATS)

$2.40 USD

2.40
20,202

-0.06 (-2.44%)

Updated Apr 25, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for OCX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for OncoCyte Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 9 20 37 8 22
Receivables 0 2 1 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 1 3 1 1 1
Total Current Assets 11 26 39 9 23
Net Property & Equipment 4 9 6 7 4
Investments & Advances 0 0 0 13 11
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 57 62 110 24 0
Deposits & Other Assets 2 2 2 2 2
Total Assets 75 100 160 55 40
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 1 2 1
Accounts Payable 1 1 2 0 0
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 6 8 10 6 3
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 2 0 0 0
Total Current Liabilities 7 12 14 9 4
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 2 2
Non-Current Capital Leases 0 0 0 0 3
Other Non-Current Liabilities 45 51 77 7 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 54 66 94 22 9
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 310 295 253 157 125
Capital Surplus 0 0 0 0 0
Retained Earnings -290 -261 -188 -124 -94
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 20 34 65 33 31
Total Liabilities & Shareholder's Equity 75 100 160 55 40
Total Common Equity 20 34 65 33 31
Shares Outstanding 8.20 5.90 4.60 3.40 2.60
Book Value Per Share 2.50 5.81 14.18 9.85 11.86

Fiscal Year End for OncoCyte Corporation falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 9 14 18 12
Receivables NA 0 2 2 2
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 1 1 1 1
Total Current Assets NA 11 17 21 16
Net Property & Equipment NA 4 4 6 6
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 57 57 57 57
Deposits & Other Assets NA 2 2 2 2
Total Assets NA 75 82 88 83
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 1 1 1 1
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 6 6 6 7
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 7 8 8 9
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 34 34 33
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 54 44 44 45
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 310 310 310 296
Capital Surplus NA 0 0 0 0
Retained Earnings NA -290 -272 -266 -258
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 20 38 44 38
Total Liabilities & Shareholder's Equity NA 75 82 88 83
Total Common Equity 0 20 38 44 38
Shares Outstanding 8.20 8.20 8.20 8.20 5.90
Book Value Per Share 0.00 2.50 4.58 5.32 6.43